HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and maintained a $15 price target.

March 06, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals has been reiterated with a Buy rating and a $15 price target by HC Wainwright & Co.
The reiteration of a Buy rating and a maintained price target of $15 by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could positively influence Rigel Pharmaceuticals' stock price in the short term. Analyst ratings, especially from well-regarded firms, often have a significant impact on how stocks are perceived in the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100